Tumor-specific delivery of clickable inhibitor for PD-L1 degradation and mitigating resistance of radioimmunotherapy
Science Advances · 15.11.2024 · 10 (46)
DOI: 10.1126/sciadv.adq3940 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 15.11.2024. Verfasst von Bo Hou und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200241, China. Hauptthemen laut MEDLINE: B7-H1 Antigen, Radioimmunotherapy, Click Chemistry, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Achieving selective and durable inhibition of programmed death ligand 1 (PD-L1) in tumors for T cell activation remains a major challenge in immune checkpoint blockade therapy. We herein presented a set of clickable inhibitors for spatially confined PD-L1 degradation and radioimmunotherapy of cancer. Using metabolic glycan engineering click bioorthogonal chemistry, PD-L1 expressed on tumor cell membranes was labeled with highly active azide groups. This enables covalently binding of the clickable inhibitor with PD-L1 and subsequent PD-L1 degradation. A pH-activatable nanoparticle responding to extracellular acidic pH of tumor was subsequently used to deliver the clickable PD-L1 inhibitor into extracellular tumor microenvironment for depleting PD-L1 on the surface of tumor cell and macrophage membranes in vivo. We further demonstrated that a combination of the clickable PD-L1 inhibitor with radiotherapy (RT) eradicated the established tumor by inhibiting RT–up-regulated PD-L1 in the tumor tissue. Therefore, selective PD-L1 blockade in tumors via the clickable PD-L1 inhibitor offers a versatile approach to promote cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200241, China.
- State Key Laboratory of Chemical Biology and Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
- Yantai Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Materia Medica, Shandong 264000, China.
- University of Chinese Academy of Sciences, Beijing 100049, China.
- State Key Laboratory of Drug Research and Small-Molecule Drug Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
- Center for Biotherapeutics Discovery Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
ORCID-Profile: Bo Hou, Jiayi Ye, Lujia Huang, Jiaxing Pan, Yujun Zhao, Haijun Yu, Zhiai Xu
Zitieren
APA
Hou, B., Ye, J., Huang, L., Cheng, W., Chen, F., Zhou, H., Pan, J., Gao, J., Lai, Y., Zhao, Y., Huang, W., Yu, H., & Xu, Z. (2024). Tumor-specific delivery of clickable inhibitor for PD-L1 degradation and mitigating resistance of radioimmunotherapy. Science Advances, 10(46). https://doi.org/10.1126/sciadv.adq3940
Vancouver
Hou B, Ye J, Huang L, Cheng W, Chen F, Zhou H, et al. Tumor-specific delivery of clickable inhibitor for PD-L1 degradation and mitigating resistance of radioimmunotherapy. Science Advances. 2024;10(46). doi:10.1126/sciadv.adq3940
BibTeX
@article{Hou2024,
author = {Hou, Bo and Ye, Jiayi and Huang, Lujia and Cheng, Wenhao and Chen, Fangmin and Zhou, Huiling and Pan, Jiaxing and Gao, Jing and Lai, Yi and Zhao, Yujun and Huang, Wei and Yu, Haijun and Xu, Zhiai},
title = {Tumor-specific delivery of clickable inhibitor for PD-L1 degradation and mitigating resistance of radioimmunotherapy},
journal = {Science Advances},
year = {2024},
volume = {10},
number = {46},
doi = {10.1126/sciadv.adq3940}
}
EUVIMED